Ildong Pharmaceutical Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-03-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.ildong.com
A Clinical Trial to Compare the Efficacy and Safety of a Combination Therapy of Ezetimibe and Rosuvastatin Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients (I-ROSETTE Study)
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2018-06-13
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 396
- Registration Number
- NCT02749994
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Clinical Trial to Compare the Pharmacokinetics of TAH Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: TAH Tablet (Telmisartan/Amlodipine besylate/Hydrochlorothiazide)Drug: TWYNSTA(Telmisartan+Amlodipine besylate)
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT02739672
- Locations
- 🇰🇷
Chonbuk National University Hospital, Chonbuk, Korea, Republic of
Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients
Phase 3
Completed
- Conditions
- Essential Hypertension
- Interventions
- Drug: Telmisartan/AmlodipineDrug: Telmisartan/Amlodipine+Hydrochlorothiazide
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2016-11-25
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 300
- Registration Number
- NCT02738632
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Dose-escalation, Repeated and Single Oral Dosing Study
Phase 1
Terminated
- Conditions
- Acute Coronary Syndrome
- Interventions
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 104
- Registration Number
- NCT02419820
A Bioequivalence Study Comparing Cilnidipine/Valsartan Combination With Coadministration of Cilnidipine and Valsartan
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- Drug: Cilnidipine/ValsartanDrug: Cilnidipine+Valsartan
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2016-01-13
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 54
- Registration Number
- NCT02343250
Bioequivalence Study to Compare the Pharmacokinetics of Besifovir in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: Treatment ADrug: Treatment B
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2016-01-13
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT02300688
Phase III Study of Rosuvastatin and Fenofibrate Versus Rosuvastatin in Mixed Dyslipidemia
- First Posted Date
- 2014-10-10
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 362
- Registration Number
- NCT02262143
- Locations
- 🇰🇷
Ildong Pharm., Seoul, Korea, Republic of
The Efficacy and Safety of a Combination Therapy of Rosuvastatin and Ezetimibe Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients
Phase 3
- Conditions
- Hypercholesterolemia
- Interventions
- Drug: Rosuvastatin/Ezetimibe
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 400
- Registration Number
- NCT02251847
- Locations
- 🇰🇷
Gil Medical Center, Seoul, Korea, Republic of
Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2014-05-22
- Last Posted Date
- 2018-06-13
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 286
- Registration Number
- NCT02145104
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Kyung-gi, Korea, Republic of
A Drug Interaction Study of Mosapride and Rebamipide
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2014-04-08
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT02106130
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath